Hikma Expands Injectable Portfolio with Furosemide Launch

Hikma Pharmaceuticals has announced the U.S. launch of Furosemide Injection, USP, in multiple dosage forms, including the first FDA-approved 50mL and 100mL presentations. This medication is indicated for the treatment of edema in adults and pediatric patients caused by conditions like heart failure, liver cirrhosis, and renal disease, as well as for acute pulmonary edema.

The introduction broadens Hikma's extensive injectable medicine portfolio, which includes over 160 products. U.S. sales for key Furosemide Injection presentations reached approximately $30 million in the 12 months ending September 2024, per IQVIA data.